Wet Age-Related Macular Degeneration Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, by DelveInsight | Ocular Therapeutix, Iveric Bio, Boehringer Ingelheim, Janssen

The Wet Age-Related Macular Degeneration Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Wet Age-Related Macular Degeneration Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Wet Age-Related Macular Degeneration Market.

Some of the key takeaways from the Wet Age-Related Macular Degeneration Pipeline Report:

• Companies across the globe are diligently working toward developing novel Wet Age-Related Macular Degeneration treatment therapies with a considerable amount of success over the years. 
• Wet Age-Related Macular Degeneration companies working in the treatment market are Akari Therapeutics, Apellis Pharmaceuticals, Shanghai Biomabs Pharmaceutical, Ocular Therapeutix, Clearside Biomedical, RemeGen, Ribomic, Isarna Therapeutics, Alkahest, Shanghai Henlius Biotech, REGENXBIO, Luye Pharma, Gemini Therapeutics, Iveric Bio, Boehringer Ingelheim, Janssen Research and Development, and others, are developing therapies for the Wet Age-Related Macular Degeneration treatment 

• Emerging Wet Age-Related Macular Degeneration therapies in the different phases of clinical trials are- Nomacopan, APL-2006, CMAB818, OTX-TKI, CLS-AX, RC 28 E, RBM-007, ISTH0036, ALK4290, HLX04-O, RGX-314, LY09004, KSI-301, Zimura, BI 836880, AAVCAGsCD59, and others are expected to have a significant impact on the Wet Age-Related Macular Degeneration market in the coming years.  
• In August 2022, OPT-302 for wet age-related macular degeneration (wet AMD) is currently undergoing Phase 3 clinical trials, and Opthea Limited has announced a non-dilutive financing transaction for up to US$170 million from investment funds working with Launch Therapeutics (Launch Tx).
• In August 2022, A new biologics licence application (BLA) for ONS-5010, an investigational ophthalmic therapy that, if approved, will be marketed as LYTENAVATM (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD), was submitted to the U.S. Food and Drug Administration (FDA) by Outlook Therapeutics, Inc
• In August 2022, In the Phase 2 “Durasert® and Vorolanib in Ophthalmology 2” (DAVIO 2) clinical trial of EYP-1901, an investigational sustained delivery anti-vascular endothelial growth factor (anti-VEGF) treatment for wet age-related macular degeneration (wet AMD), EyePoint Pharmaceuticals, Inc. reported that the first patient had been dosed
• In August 2022, A definitive merger agreement between Alcon and Aerie Pharmaceuticals, Inc. was announced, under which Alcon will purchase Aerie.
• In February 2021, In order to investigate the pharmacodynamics of two doses in two formulations of the RGX-314 gene therapy administered through subretinal delivery in participants with neovascular age-related macular degeneration, REGENXBIO Inc. launched a Phase II, open-label study
• In December 2021, In order to assess the effectiveness and safety of RGX-314 gene therapy in patients with nAMD, REGENXBIO Inc. started a andomized, partially masked, controlled, Phase III clinical research. The two dose levels of RGX-314 gene therapy will be compared to an active comparator in the trial. The best-corrected visual acuity (BCVA) of RGX-314 relative to aflibercept was measured as the study’s main outcome. Participants who match the inclusion/exclusion criteria will be assigned to one of three arms, totaling about 465

Get a Free Sample PDF Report to know more about Wet Age-Related Macular Degeneration Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-pipeline-insight

Emerging Wet Age-Related Macular Degeneration Drugs Under Different Phases of Clinical Development Include:

• Nomacopan: Akari Therapeutics
• APL-2006: Apellis Pharmaceuticals
• CMAB818: Shanghai Biomabs Pharmaceutical
• OTX-TKI: Ocular Therapeutix
• CLS-AX: Clearside Biomedical
• RC 28 E: RemeGen
• Abicipar pegol: Molecular Partners
• SOK583A1: Sandoz
• BA9101 (LY09004): Shandong Boan Biotechnology Co. Ltd.
• ADVM-022: Adverum Biotechnologies
• RBM-007: Ribomic
• ISTH0036: Isarna Therapeutics
• ALK4290: Alkahest
• HLX04-O: Shanghai Henlius Biotech
• RGX-314: REGENXBIO
• LY09004: Luye Pharma
• KSI-301: Gemini Therapeutics
• Zimura: Iveric Bio
• BI 836880: Boehringer Ingelheim
• AAVCAGsCD59: Janssen Research and Development

Route of Administration

Wet Age-Related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Wet Age-Related Macular Degeneration Pipeline Therapeutics Assessment

• Wet Age-Related Macular Degeneration Assessment by Product Type
• Wet Age-Related Macular Degeneration By Stage and Product Type
• Wet Age-Related Macular Degeneration Assessment by Route of Administration
• Wet Age-Related Macular Degeneration By Stage and Route of Administration
• Wet Age-Related Macular Degeneration Assessment by Molecule Type
• Wet Age-Related Macular Degeneration by Stage and Molecule Type

DelveInsight’s Wet Age-Related Macular Degeneration Report covers around 80+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Wet Age-Related Macular Degeneration product details are provided in the report. Download the Wet Age-Related Macular Degeneration pipeline report to learn more about the emerging Wet Age-Related Macular Degeneration therapies

Some of the key companies in the Wet Age-Related Macular Degeneration Therapeutics Market include:

Key companies developing therapies for Wet Age-Related Macular Degeneration are – Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Isarna Therapeutics, IVERIC bio (formerly Ophthotech Corporation), Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc, Alkahest, Tyrogenex, Iconic Therapeutics, AiViva BioPharma, Boehringer Ingelheim, RemeGen, PanOptica, Clearside Biomedical, Feramda, AsclepiX Therapeutics, Unity Biotechnology, Kyowa Kirin, Ocular Therapeutix, Janssen Research & Development, EyePoint Pharmaceuticals, Shanghai Biomabs Pharmaceutical, Aerie Pharmaceuticals, Ashvattha Therapeutics, Roche, Sunshine Guojian Pharmaceutical (Shanghai), Adverum Biotechnologies, TOT Biopharm, 4D Molecular Therapeutics, Abpro Corporation, Novelty Nobility, Kala Pharmaceuticals, Surrozen, Eyevensys, Ocugen, Exonate, and others.

Wet Age-Related Macular Degeneration Pipeline Analysis:

The Wet Age-Related Macular Degeneration pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Wet Age-Related Macular Degeneration with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Wet Age-Related Macular Degeneration Treatment.
• Wet Age-Related Macular Degeneration key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Wet Age-Related Macular Degeneration Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Wet Age-Related Macular Degeneration market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Wet Age-Related Macular Degeneration drugs and therapies

Wet Age-Related Macular Degeneration Pipeline Market Drivers

• Rise in ageing population, entry of biosimilars, robust pipeline are some of the important factors that are fueling the Wet Age-Related Macular Degeneration Market.

Wet Age-Related Macular Degeneration Pipeline Market Barriers

• However, burden of medical treatment, high cost associated with antiVEGF agents, decrease in quality of life and other factors are creating obstacles in the Wet Age-Related Macular Degeneration Market growth.

Scope of Wet Age-Related Macular Degeneration Pipeline Drug Insight    

• Coverage: Global
• Key Wet Age-Related Macular Degeneration Companies: Akari Therapeutics, Apellis Pharmaceuticals, Shanghai Biomabs Pharmaceutical, Ocular Therapeutix, Clearside Biomedical, RemeGen, Ribomic, Isarna Therapeutics, Alkahest, Shanghai Henlius Biotech, REGENXBIO, Luye Pharma, Gemini Therapeutics, Iveric Bio, Boehringer Ingelheim, Janssen Research and Development, and others
• Key Wet Age-Related Macular Degeneration Therapies: Nomacopan, APL-2006, CMAB818, OTX-TKI, CLS-AX, RC 28 E, RBM-007, ISTH0036, ALK4290, HLX04-O, RGX-314, LY09004, KSI-301, Zimura, BI 836880, AAVCAGsCD59, and others
• Wet Age-Related Macular Degeneration Therapeutic Assessment: Wet Age-Related Macular Degeneration current marketed and Wet Age-Related Macular Degeneration emerging therapies
• Wet Age-Related Macular Degeneration Market Dynamics: Wet Age-Related Macular Degeneration market drivers and Wet Age-Related Macular Degeneration market barriers 

Request for Sample PDF Report for Wet Age-Related Macular Degeneration Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services